Roche's Oral GLP-1 Receptor Agonist CT-996 Shows Promising Early Clinical Results with 14-Pound Weight Loss in 4 Weeks

Sep 12, 2024 07:44 CST Updated 07:45

Roche

Oncology Drug Research, Development, and Manufacturing

▎WuXiEdited by Kant Content Team

Today, Roche announced the Phase 1 clinical trial results of its oral glucagon-like peptide-1 (GLP-1) receptor agonist CT-996 at the 2024 European Association for the Study of Diabetes (EASD) Annual Meeting. The latest results show,CT-996 Reduced Participants' Body Weight by 7.3% (Approximately 7 kg) Over Four Weeks in Obese Individuals Without Type 2 Diabetes.Based on this positive result, the company plans to initiate Phase 2 clinical trials in 2025.

This study is a multiple-dose, dose-escalation study that enrolled obese participants without type 2 diabetes who received different doses of CT-996 or placebo. The trial results showed,In the subgroup of patients in Cohort 3 (who underwent a slower dose titration and eventually reached 120 mg), once-daily oral CT-996 reduced body weight by an average of 7.3% within 4 weeks, compared to a 1.2% reduction with placebo during the same period. CT-996 provided clinically meaningful weight loss compared to placebo.

▲Weight loss effect of CT-996 (Image source: Reference [1])

In terms of safety, allTreatment-relatedAll treatment-emergent adverse events (TEAEs) were mild or moderate, with no Grade 3 or higher TEAEs reported. No discontinuations of the study drug due to TEAEs were observed. The most common TEAEs were gastrointestinal-related events, consistent with other incretin-based therapies. Participants receiving higher doses experienced more TEAEs, but slower dose titration may improve tolerability.

CT-996 is a once-daily oral GLP-1 receptor small molecule agonist.Roche reached a merger agreement with Carmot Therapeutics last December, acquiring the company for approximately $3.1 billion and gaining access to multiple clinical-stage subcutaneous and oral incretin therapies, including CT-996.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Safety, Pharmacokinetics, and Pharmacodynamics of CT-996, an Oral Small-Molecule, Signal-Biased GLP-1 Receptor Agonist Over 4 Weeks in Adults With Obesity. Retrieved September 11, 2024, from https://medically.roche.com/global/en/metabolism/easd-2024/medical-material/EASD-2024-presentation-chakravarthy-ct-996-an-oral-small-molecule-signal-biased-pdf.html

[2] Roche says its Carmot-acquired obesity pill is effective in early study. Retrieved September 11, 2024, from https://endpts.com/roche-says-its-carmot-acquired-obesity-pill-is-effective-in-early-study/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.

Share，PointLike，In View, Focus on Global Biomedical Health Innovation